Posted by Michael Wonder on 06 Jan 2026
NICE recommends new treatment option for highly active multiple sclerosis
2 January 2026 - Thousands of people living with a form of multiple sclerosis will benefit from greater treatment choice, following new guidance from NICE.
NICE has recommended natalizumab, as an option for adults with relapsing-remitting multiple sclerosis that remains highly active after a full course of at least one disease-modifying therapy, and for whom another treatment called cladribine is not suitable.
